spaa begins in a pioneering study that may change the diagnostic and monitoring of hypertensive patients.

EVOLVE study  ms have 4,000 patients and aims to demonstrate that new systems of the pressure monitorizacin pressure, MAP and AMPA, improve prediccin of cardiovascular complications and, consequently, may contribute to the reduction of morbidity and mortality in hypertensive patients.

 hypertensin The estimated pressure and its consequences are the leading cause of mortality in Espaay, despite this, experts believe that their control is an "inadequate".

 One in three adults suffer hypertensin spaniards pressure.

Reported CARDIORISC  study, which evaluated 100,000 patients leads to arterial hypertensin Espaa, 50% of treated hypertensives is not well controlled your blood press on.

 in addition, this study reveals that conventional medicine is overdiagnosis about 30% of patients.

Arranca en Espaa clinician an ambitious study that may significantly improve the management of blood on our pas hypertensin. Under the name of EVOLVE and an estimated participation of 4,000 ms prediabticos patients and diabetics, the Society of hypertensin Espaola Espaola-League for the Fight Against Blood hypertensin (SEH-LELHA), together with the association so the prevention of cardiovascular risk (PRECAN) and ulcer, intends to see that the new systems of blood monitorizacin of the pressure, MAP (monitorizacin ambulatory blood pressure of the pressure for 24 hours) and AMPA (self medicate pressure of the pressure) are tcnico ms accurate in the diagnostic and monitoring of patients and therefore may contribute in the reduction of morbidity and mortality in hypertensive patients. An advance of great impact if we consider that one in three adults has hypertensin Espaa.

The EVOLVE study is the first step toward a major in evolucin hypertensin management, said Dr. Luis Miguel Ruilope chief hypertensin Unit of Hospital 12 de Octubre de Madrid and member of the Sociedad-Liga hypertensin Espaola of Espaola to Combat hypertensin Arterial (SEH-LELHA) for the submission of this work was held today within the framework of the 14th meeting of the SEH-LELHA. This is a RESEARCH that will offer a considerable improvement for many patients so far diagnosed or over-medicated at risk of suffering a heart attack, stroke, cardiac and renal failure, and premature death. Being a world reference as it is the first study to be conducted including the MAP and AMPA as systems for monitoring blood hypertensin has aadido Dr. Julin Segura, Specialist Unit of hypertensin the Hospital 12 de Octubre.

The tcnico of diagnostics and monitoring in hypertensive patients is the same for many DCAD. Therefore urges the implantacin of a system that reliably detected for ms real tension value and therefore help the physician to better control hypertensin, said Dr. Pedro Aranda, president of the SEH-LELHA.

The EVOLVE study is the result of the findings of the CARDIORISC project, an initiative undertaken by the SEH nica-ao LELHA in 2004 and has been installing 1,200 ms ambulatory MAP in all Espaa and assess nearly 100,000 people with hypertension with this technique. The clinician anlisis-epidemiolgico of the measures taken in these patients indicates that the control of the pressure reaches 50% pressure using ABPM, compared to 25% is achieved with the system of medici No conventional explains Dr. Aranda.

This difference is due to the fact that the conventional medical system pressure of the pressure, many patients experience changes in their numbers motivated by nervousness that makes them take of the pressure the blood in your query , which is known to Sndrome white coat. The MAP, however, to take The pressure at home and every 20 minutes during 24 hours, eliminates this effect, and in addition, provides information on nocturnal blood The pressure, variable which is related very closely with the sighting of cardiovascular events.

About EVOLVE study
 This is an observational study that includes annual monitoring for 4 years, and who have an estimated sample of 4041 patients and diabetics prediabticos.

 The main objective is to evaluate the value of the pressure Prognosis blood, determined by different measurement tcnico (PA clinician, AMPA and MAP), the incidence of cardiovascular events in hypertensive patients with diabetes Type 2 or prediabticos.

 Having the participation of special schools in Occupational Medicine, Primary centers and units Caution hypertensin hospital.

 The results of this study are called to lay the groundwork for the application in the experience Training of health surveillance information that facilitates the MAP. Supondrn results that the establishment of the MAP as indispensable in the diagnosis and monitoring of hypertension. It is, therefore, one that aims RESEARCH final response to the urgent need to improve the approach of HBP.

CARDIORISC reaches 100,000 patient-controlled MAP
Consolidndose as follows CARDIORISC largest database of MAP worldwide this month after achieving the 100,000 patients evaluated monitorizacin system of the pressure ambulatory blood 24 hours.

CARDIORISC continuous growth recorded since its inception in 2004, shows its consolidaciny as it reaffirms the largest database of maps of all Europe. CARDIORISC platform, driven by SEH-LELHA in liaison with ulcer, a laboratory that has established itself as the center and engine of knowledge about cardiovascular risk, plans to continue this upward trend, for which last move by introducing new tcnico diagnosis that improve the cardiovascular risk integral Benchmarks.